Current Hematologic Malignancy Reports

, Volume 3, Issue 3, pp 167–173 | Cite as

Pediatric non-Hodgkin lymphoma

Article

Abstract

Non-Hodgkin lymphoma (NHL) accounts for 7% of cancer in children and adolescents in the United States, or approximately 1000 cases annually. NHL in the pediatric population differs from that observed in adult patients with respect to staging systems, histologic subtypes of disease, treatment, and outcomes. Although more than 90% of pediatric NHL is of high-grade histology, more than 80% of patients achieve long-term event-free survival with modern therapy. This review focuses on current treatments for pediatric NHL and some of the differences between NHL observed in pediatric and adult patients.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    O’Leary M, Sheaffer J, Keller F, et al.: Lymphomas and reticuloendothelial neoplasms. In Cancer Epidemiology in Older Children and Young Adults 15–29 Years of Age, Including SEER Incidence and Survival: 1975–2000. Edited by Bleyer A, O’Leary M, Barr R, et al.: NIH pub. No. 06-5767: Bethesda, MD: National Cancer Institute; 2006:25–38.Google Scholar
  2. 2.
    Sandlund JT, Downing JR, Crist WM: Non-Hodgkin’s lymphoma in childhood. N Engl J Med 1996, 334:1238–1248.PubMedCrossRefGoogle Scholar
  3. 3.
    Gross TG, Shiramizu B: Lymphoproliferative disorders related to immunodeficiencies. In Pediatric Lymphomas. Edited by Weinstein HJ, Hudson MM, Link MP. New York: Springer-Verlag; 2007:233–258.CrossRefGoogle Scholar
  4. 4.
    Seidemann K, Tiemann M, Henze G, et al.: Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999, 33:536–544.PubMedCrossRefGoogle Scholar
  5. 5.
    Gross TG, Bucuvalas JC, Park JR, et al.: Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005, 23:6481–6488.PubMedCrossRefGoogle Scholar
  6. 6.
    Murphy SB, Fairclough DL, Hutchison RE, et al.: Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989, 7:186–193.PubMedGoogle Scholar
  7. 7.
    Sabesan V, Cairo MS, Lones MA, et al.: Assessment of minimal residual disease in childhood non-Hodgkin lymphoma by polymerase chain reaction using patient-specific primers. J Pediatr Hematol Oncol 2003, 25:109–113.PubMedCrossRefGoogle Scholar
  8. 8.
    Campana D, Coustan-Smith E, Sandlund JT, Abromowitch M: A novel approach for staging and minimal residual disease detection in patients with T-cell lymphoblastic lymphoma: a Children’s Oncology Group study. Ann Oncol 2005, 16(Suppl 5):62.Google Scholar
  9. 9.
    Burkhardt B, Zimmermann M, Oschlies I, et al.: The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131:39–49.PubMedCrossRefGoogle Scholar
  10. 10.
    Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835–3849.PubMedGoogle Scholar
  11. 11.
    Oschlies I, Klapper W, Zimmermann M, et al.: Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006, 107:4047–4052.PubMedCrossRefGoogle Scholar
  12. 12.
    Miles RR, Raphael M, McCarthy K, et al.: Expression of BCL2 and C-MYC in pediatric diffuse large B-cell lymphoma. Pediatr Blood Cancer 2006, 46:860.Google Scholar
  13. 13.
    Dave SS, Fu K, Wright GW, et al.: Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 2006, 354:2431–2442.PubMedCrossRefGoogle Scholar
  14. 14.
    Seidemann K, Tiemann M, Lauterbach I, et al.: Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol 2003, 2:1782–1789.CrossRefGoogle Scholar
  15. 15.
    Patte C, Auperin A, Gerard M, et al.: Results of randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce tretment for early responding patients. Blood 2007, 109:2773–2780.PubMedGoogle Scholar
  16. 16.
    Rosenwald A, Wright G, Leroy K, et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of e large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851–862.PubMedCrossRefGoogle Scholar
  17. 17.
    Cairo MS, Gerard M, Sposto R, et al.: Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109:2736–2743.PubMedGoogle Scholar
  18. 18.
    Woessmann W, Seidemann K, Mann G, et al.: The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005, 105:948–958.PubMedCrossRefGoogle Scholar
  19. 19.
    Link MP, Shuster JJ, Donaldson SS, et al.: Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med 1997, 337:1259–1266.PubMedCrossRefGoogle Scholar
  20. 20.
    Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999, 94:3294–3306.PubMedGoogle Scholar
  21. 21.
    Patte C, Auperin A, Michon J, et al.: The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001, 97:3370–3379.PubMedCrossRefGoogle Scholar
  22. 22.
    Pfeundschuh M Trumper L, Osterborg A, et al.: CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379–391.CrossRefGoogle Scholar
  23. 23.
    Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma. (DL-BCL). Blood 2003, 101:4279–4284.PubMedCrossRefGoogle Scholar
  24. 24.
    Thomas DA, Faderl S, O’Brien S, et al.: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106:1569–1580.PubMedCrossRefGoogle Scholar
  25. 25.
    Reatz EA, Perkins SL, Bhojwani D, et al.: Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006, 47:130–140.CrossRefGoogle Scholar
  26. 26.
    Anderson JR, Jenkin RD, Wilson JF, et al.: Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s lymphoma: a report of CCG-551 from the Children’s Cancer Group. J Clin Oncol 1993, 11:1024–1032.PubMedGoogle Scholar
  27. 27.
    Burkhardt B, Woessmann W, Zimmermann M, et al.: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24:491–499.PubMedCrossRefGoogle Scholar
  28. 28.
    Asselin BL, Shuster J, Amylon M, et al.: Improved event-free survival (EFS) with high-dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Proc ASCO 2001, 20:367.Google Scholar
  29. 29.
    Leung W, Sandlund JT, Hudson MM, et al.: Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer 2001, 92:1959–1966.PubMedCrossRefGoogle Scholar
  30. 30.
    Reiter A, Schrappe M, Ludwig WD, et al.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000, 95:416–421.PubMedGoogle Scholar
  31. 31.
    Hoelzer D, Gokbuget N, Digel W, et al.: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002, 99:4379–4385.PubMedCrossRefGoogle Scholar
  32. 32.
    Ferrando AA, Neuberg DS, Staunton J, et al.: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75–87.PubMedCrossRefGoogle Scholar
  33. 33.
    Coustan-Smith E, Sancho J, Hancock ML, et al.: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002, 100:2399–2402.PubMedCrossRefGoogle Scholar
  34. 34.
    Duyster J, Bai RY, Morris SW: Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001, 20:5623–5637.PubMedCrossRefGoogle Scholar
  35. 35.
    Seidemann K, Tiemann M, Schrappe M, et al.: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 2001, 97:3699–3706.PubMedCrossRefGoogle Scholar
  36. 36.
    Kumar S, Pittaluga S, Raffeld M, et al.: Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol 2005, 8:52–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Hinshaw M, Trowers AB, Kodish E, et al.: Three children with CD30 cutaneous anaplastic large cell lymphomas bearing the t(2;5)(p23;q35) translocation. Pediatr Dermatol 2004, 21:212–217.PubMedCrossRefGoogle Scholar
  38. 38.
    Laver JH, Kraveka JM, Hutchison RE, et al.: Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005, 23:541–547.PubMedCrossRefGoogle Scholar
  39. 39.
    Laver JH, Mahmoud H, Pick TE, et al.: Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin’s lymphoma: a Pediatric Oncology Group study. Leuk Lymphoma 2001, 42:399–405.PubMedCrossRefGoogle Scholar
  40. 40.
    Falini B, Pileri S, Zinzani PL, et al.: ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999, 93:2697–2706.PubMedGoogle Scholar
  41. 41.
    Brugières L, Quartier P, Le Deley MC, et al.: Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53–58.PubMedCrossRefGoogle Scholar
  42. 42.
    Bartlett NL, Bernstein SH, Leonard JP, et al.: Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30) monoclonal antibody in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2003, 102:647.Google Scholar
  43. 43.
    Sausville EA, Arbuck SG, Messmann R, et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001, 19:2319–2333.PubMedGoogle Scholar
  44. 44.
    Attarbaschi A, Dworzak M, Steiner M, et al.: Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. Pediatr Blood Cancer 2005, 44:70–76.PubMedCrossRefGoogle Scholar
  45. 45.
    Lorsbach RB, Shay-Seymore D, Moore J, et al.: Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002, 99:1959–1964.PubMedCrossRefGoogle Scholar
  46. 46.
    Abla O, Weitzman S: Primary central nervous system lymphoma in children. Neurosurg Focus 2006, 21:1–8.CrossRefGoogle Scholar
  47. 47.
    Claviez A, Meyer U, Dominick C, et al.: MALT lymphoma in children: a report from the NHL-BFM study group. Pediatr Blood Cancer 2006, 47:210–214.PubMedCrossRefGoogle Scholar
  48. 48.
    Rosh JR, Gross T, Mamula P, et al.: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007, 13:1024–1030.PubMedCrossRefGoogle Scholar
  49. 49.
    Carbone PP, Kaplan HS, Musshoff K, et al.: Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971, 31:1860–1861.PubMedGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Department of Pediatrics, The Ohio State University School of MedicineDivision of Hematology/Oncology/BMT, Children’s HospitalColumbusUSA

Personalised recommendations